Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental cancer drug trial halted early

NCT ID NCT06188208

Disease control Sponsor: Vividion Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called VVD-130850, which blocks a protein (STAT3) that helps cancers grow. The trial aimed to find a safe dose and see if the drug works, both alone and with another immunotherapy, in people with advanced solid tumors or blood cancers. The study was terminated before completion, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

132 people

The number who actually took part.

Started

Jan 2024

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Histologically or cytologically confirmed metastatic or unresectable solid tumor or advanced non-Hodgkin's lymphoma (NHL). 2. Eastern Cooperative Oncology Group (ECOG) performance status ≤1. 3. Adequate organ and bone marrow function as defined in the protocol. 4. For Combination Therapy Expansion: * Serine/threonine kinase 11/ liver kinase B1 (STK11/LKB1) mutated non-small cell lung cancer (NSCLC) as assessed by historical (local) test. * Must be refractory to or have progressed on or after a platinum-based doublet regimen and an immune checkpoint inhibitor (CPI). These therapies could have been given in the same line of therapy or different lines of therapy. 5. Measurable disease by RECIST version 1.1 as assessed by the Investigator. Key Exclusion Criteria: 1. Have a diagnosis of immunodeficiency or are receiving systematic steroid therapy or any other form of immunosuppressive therapy. 2. Prior allogeneic transplantation. 3. History of cardiac diseases as defined in detail in the protocol. 4. Clinically significant infection or any eye infection. 5. Active central nervous system (CNS) malignancies (previously treated CNS malignancies are not exclusionary). 6. Combination Therapy Expansion: * Known hypersensitivity or contraindication to pembrolizumab or any of its components. * Any prior toxicity (Grade 3 or 4) related to immunotherapy leading to treatment discontinuation with the exception of the history of immunotherapy-related endocrinopathy controlled with ongoing medical management (e.g., hypothyroidism, adrenal insufficiency, diabetes).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced hematologic tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm neoplasm non-Hodgkin lymphoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced hematologic tumors Advanced solid tumors

Contacts and locations

Locations

  • Blacktown Hospital

    Blacktown, New South Wales, Australia

  • California Research Institute

    Los Angeles, California, 90027, United States

  • Cancer Research South Australia

    Adelaide, Australia

  • Florida Cancer Specialists

    Sarasota, Florida, 34232, United States

  • Gold Coast University Hospital

    Southport, Queensland, Australia

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • ICON Cancer Research

    South Brisbane, Australia

  • MDACC

    Houston, Texas, 77030, United States

  • NEXT Austin

    Austin, Texas, 78758, United States

  • NEXT Dallas

    Irving, Texas, 75039, United States

  • NEXT Madrid

    Madrid, Spain

  • NEXT San Antonio

    San Antonio, Texas, 78299, United States

  • NEXT Virginia

    Fairfax, Virginia, 22031, United States

  • Orange Health Service

    Orange, New South Wales, Australia

  • START Barcelona Hospital HM Nou Delfos

    Barcelona, Spain

  • START Madrid CIOCC

    Madrid, Spain

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • Start Madrid-FJD, Hospital Fundacion Jimenez Diaz

    Madrid, Spain

  • University of Utah Huntsman Cancer Institute

    Salt Lake City, Utah, 84112, United States

  • Vall d'Hebron

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.